Brief: N2off Stockholders Approve Merger With Drug Discovery Company Targeting Resistant Cancers Including Pancreatic And Non-Small Cell Lung Cancer

Nexentis Technologies

25/09/2025 22:58

Sept 25 (Reuters) - N2OFF Inc NITO.O:

N2OFF STOCKHOLDERS APPROVE MERGER WITH DRUG DISCOVERY COMPANY TARGETING RESISTANT CANCERS INCLUDING PANCREATIC AND NON-SMALL CELL LUNG CANCER

Source text: ID:nGNX2M4ybK

Further company coverage: NITO.O

 ((Reuters.Briefs@thomsonreuters.com;))